Identifying the Fast-acting Antidepressant Signatures of Treatment Response with...
Identifying the Fast-acting Antidepressant Signatures of Treatment Response with psychedelic compounds using a novel behavioral tracking system and single-cell resolution
Mental health disorders affect 84 million people across Europe and are associated with an economic burden of €600 billion/year. New evidence from clinical trials suggests that a single treatment with psychedelic compounds, such as...
Mental health disorders affect 84 million people across Europe and are associated with an economic burden of €600 billion/year. New evidence from clinical trials suggests that a single treatment with psychedelic compounds, such as psilocybin, can produce a fast (hours) and sustained (months) antidepressant (AD) response. However, many questions still remain about its mechanism of action, due to methodological challenges such as lack of knowledge of the brain cells and circuits where AD effects are taking place and limitations of the behavioral tests used to examine AD activity in rodents. Combining molecular, behavioral and advanced computational tools, FASTer will establish a groundbreaking and automatic behavioral tracking system to deconstruct the behavioral language associated with treatment response. In addition, FASTer will identify the brain cells and circuits responsible for the fast-acting and sustained AD effects of psilocybin. This is a move away from the traditional assessment of single behavioral readouts to unconventional group behaviors and endophenotypes in a translationally-relevant context that will cause a paradigm shift and revolutionize the field of behavioral phenotyping. Thanks to my unique know-how in bridging human and pre-clinical psychiatry, and to go beyond the state-of-the-art, I will combine activity-dependent labelling techniques and single-cell methods to identify the genes and brain circuits engaged during psilocybin treatment. To address the multidimensional nature of psychiatric disorders, I will manipulate gene networks related to the AD effects of psilocybin. The ambitious and innovative studies proposed here have the potential to change our understanding of psychiatric disorders, and transform the field of behavioral neuroscience. Ultimately, FASTer holds tremendous promise for translatability of preclinical findings and impacting the development of fast-acting and efficacious treatments for psychiatric disorders.ver más
02-11-2024:
Generación Fotovolt...
Se ha cerrado la línea de ayuda pública: Subvenciones destinadas al fomento de la generación fotovoltaica en espacios antropizados en Canarias, 2024
01-11-2024:
ENESA
En las últimas 48 horas el Organismo ENESA ha otorgado 6 concesiones
01-11-2024:
FEGA
En las últimas 48 horas el Organismo FEGA ha otorgado 1667 concesiones
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.